ImmunoPET in Multiple Myeloma—What? So What? Now What?

ImmunoPET in Multiple Myeloma—What? So What? Now What?

Despite constant progress over the past three decades, multiple myeloma (MM) is still an incurable disease, and the identification of new biomarkers to better select patients and adapt therapy is more relevant than ever. Recently, the introduction of therapeutic monoclonal antibodies (mAbs) (includi...

Full description

Bibliographic Details
Main Authors: Clément Bailly, Benjamin Chalopin, Sébastien Gouard, Thomas Carlier, Patricia Remaud-Le Saëc, Séverine Marionneau-Lambot, Philippe Moreau, Cyrille Touzeau, Françoise Kraeber-Bodere, Caroline Bodet-Milin, Michel Chérel
Format: Article
Language:English
Published: MDPI AG 2020-06-01
Series:Cancers
Subjects:
immunoPET
multiple myeloma
immunotherapy
precision imaging
companion imaging agents
heterogeneity
Online Access:https://www.mdpi.com/2072-6694/12/6/1467

Internet

https://www.mdpi.com/2072-6694/12/6/1467

Similar Items